StudyFinder
A Phase 1, Open-label Study of Oral BDTX-4933 in Patients with KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms
Status: Recruiting
This study is testing the study drug BDTX-4933 in people with locally advanced (unresectable) or metastatic solid tumors that are characterized by a KRAS, BRAF, or NRAS mutation/alteration(s). The primary objective of the study is to assess how well participants tolerate the drug and if it is effective.
Sex: Male or Female
Age Group: 18 years and over
Inclusion Criteria:
• recurrent or advanced (unresectable) or metastatic solid tumors or histiocytic neoplasms with documented RAS or BRAF mutations
• exhausted all available standard-of-care therapies
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:
• cancer that has a known MEK1/2 mutation
• ongoing anticancer or radiation therapy
• women who are pregnant or breastfeeding
Interventions:
Drug: BDTX-4933
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), metastatic cancer, RAS or BRAF mutations, Recurrent cancer
Study Contact: Elizabeth Mollen - molle086@umn.edu
Principal Investigator: Ajay Prakash
Phase: PHASE1
IRB Number: STUDY00021016
See this study on ClinicalTrials.gov